MAIA

MAIA Biotechnology, Inc.

Insiders buying nowCIK 1878313

MAIA Biotechnology, Inc. insider trading

MAIA Biotechnology, Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.

From SEC filings · last 30 days

Recent MAIA insider transactions

The filing store could not be read just now — this page tries again on its next refresh. The filings themselves are on SEC EDGAR.

SEC Form 4 data, Q3 2024 to Q2 2026

MAIA insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded MAIA on the open market: 33 purchases worth $1.8M and 0 sales. In the last four quarters alone: 20 purchases ($653.1K) and 0 sales, by 6 insiders.

QuarterBoughtSold
Q2 2026+$204.3K3 buys—
Q1 2026——
Q4 2025+$448.8K17 buys—
Q3 2025——
Q2 2025+$180K3 buys—
Q1 2025+$272.5K4 buys—
Q4 2024+$731K6 buys—
Q3 2024——
Largest purchase
+$251K of MAIA by Smith Stan (Director) on Nov 01, 2024.

Open-market transactions through Jun 30, 2026most recent first

  • Vitoc Vlad

    Chief Executive Officer · Director

    +$101.1K

    Jun 01, 2026

    72,700 sh · $1.39

  • Smith Stan

    Director

    +$100.5K

    Jun 01, 2026

    75,000 sh · $1.34

  • Gryaznov Sergei

    Chief Scientific Officer

    +$2.7K

    Jun 01, 2026

    2,000 sh · $1.35

  • Louie Ngar Yee

    Director

    +$99.7K

    Dec 22, 2025

    81,699 sh · $1.22

  • Smith Stan

    Director

    +$69.8K

    Dec 22, 2025

    57,189 sh · $1.22

  • Chaouki Steven M

    Director

    +$49.8K

    Dec 22, 2025

    40,849 sh · $1.22

  • Smith Stan

    Director

    +$5.5K

    Dec 05, 2025

    4,580 sh · $1.20

  • Smith Stan

    Director

    +$5.5K

    Dec 05, 2025

    4,580 sh · $1.19

  • Vitoc Vlad

    Chief Executive Officer · Director

    +$57K

    Nov 28, 2025

    50,000 sh · $1.14

  • Luput Cristian

    Director

    +$20.1K

    Nov 28, 2025

    18,145 sh · $1.11

  • Vitoc Vlad

    Chief Executive Officer · Director

    +$23.1K

    Nov 26, 2025

    22,000 sh · $1.05

  • Luput Cristian

    Director

    +$21.6K

    Nov 26, 2025

    20,000 sh · $1.08

  • Smith Stan

    Director

    +$15.6K

    Nov 26, 2025

    15,000 sh · $1.04

  • Smith Stan

    Director

    +$14.7K

    Nov 25, 2025

    15,000 sh · $0.98

  • Vitoc Vlad

    Chief Executive Officer · Director

    +$10.2K

    Nov 25, 2025

    10,500 sh · $0.97

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Don't check MAIA — let it ping you

Watch every insider filing the minute it clears the SEC

The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.

MAIA Biotechnology, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.

Other companies insiders are buying now

Questions

How much MAIA stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 7 MAIA Biotechnology, Inc. insiders made 33 open-market purchases worth $1.8M and no sales. In the four quarters to Jun 30, 2026: 20 purchases ($653.1K) and no sales. The largest purchase was Smith Stan buying $251K on Nov 01, 2024.
Where does MAIA insider trading data come from?
From the Form 4 filings MAIA Biotechnology, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.